Last reviewed · How we verify
BIIX 1 XX - single rising dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BIIX 1 XX - single rising dose (BIIX 1 XX - single rising dose) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BIIX 1 XX - single rising dose TARGET | BIIX 1 XX - single rising dose | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BIIX 1 XX - single rising dose CI watch — RSS
- BIIX 1 XX - single rising dose CI watch — Atom
- BIIX 1 XX - single rising dose CI watch — JSON
- BIIX 1 XX - single rising dose alone — RSS
Cite this brief
Drug Landscape (2026). BIIX 1 XX - single rising dose — Competitive Intelligence Brief. https://druglandscape.com/ci/biix-1-xx-single-rising-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab